Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $40.8571.

Several brokerages have issued reports on LYEL. Citizens Jmp reissued a "market outperform" rating and issued a $34.00 price objective on shares of Lyell Immunopharma in a research note on Monday, June 15th. Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a report on Sunday, May 10th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a research note on Friday, August 14th. B. Riley Financial began coverage on Lyell Immunopharma in a report on Wednesday, July 22nd. They set a "buy" rating and a $44.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They issued a "buy" rating and a $36.00 price objective on the stock.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its stake in Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company's stock worth $2,335,000 after purchasing an additional 76,921 shares in the last quarter. MWG Caph Ltd purchased a new position in Lyell Immunopharma during the 4th quarter worth $31,030,000. venBio Partners LLC bought a new stake in Lyell Immunopharma during the 2nd quarter valued at $4,744,643. Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma in the 1st quarter worth $959,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Lyell Immunopharma in the 2nd quarter worth $347,000. Institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $14.37 on Monday. The company has a fifty day moving average of $14.10 and a two-hundred day moving average of $17.59. The firm has a market capitalization of $352.06 million, a price-to-earnings ratio of -1.12 and a beta of -0.04. Lyell Immunopharma has a 52 week low of $11.47 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Equities research analysts anticipate that Lyell Immunopharma will post -7.2 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source